Savithri Ramurthy

Publications by Year

Research Areas

Melanoma and MAPK Pathways, Cancer Mechanisms and Therapy, Colorectal Cancer Treatments and Studies, Advanced Breast Cancer Therapies, Protein Kinase Regulation and GTPase Signaling

Most-Cited Works

• → Towards the sustainable discovery and development of new antibiotics(2021)1,114 cited
• → Discovery of Potent and Selective RSK Inhibitors as Biological Probes(2015)83 cited
• → Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors(2008)76 cited
• → 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors(2006)70 cited
• → Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma(2015)54 cited
• → Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers(2017)44 cited
• → Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF(2018)40 cited
• → Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3(2017)39 cited
• → Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic(2019)38 cited
• → Inhibition of prenylated KRAS in a lipid environment(2017)31 cited